Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/30/2021 | $21.00 | Overweight | Morgan Stanley |
| 11/30/2021 | Outperform | Cowen & Co. | |
| 11/30/2021 | $20.00 | Buy | Jefferies |
NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that Marjan Shamsaei, PharmD, joined the company as SVP, Commercial Development and Portfolio Lead for IO102-IO103, the company's lead cancer vaccine candidate currently in a pivotal Phase 3 trial. Ms. Shamsaei joins the company's executive team, reporting to IO Biotech CEO Mai-Britt Zocca, Ph.D., and is based in the United States. "Marjan's extensive oncology product commercialization and growth strategy expertise will be invaluable as we progress into the commercia
NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that Faiçal Miyara, Ph.D., has been appointed as the company's chief business officer. Dr. Miyara, who has more than 17 years of experience in the pharmaceutical industry, will be responsible for global business development activities including strategic partnerships. Dr. Miyara will be based in the United States, report to IO Biotech's CEO, Mai-Britt Zocca, Ph.D., and be a member of the company's executive team, effective immediately. "We are very excited to welcome
Completed enrollment of pivotal Phase 3 trial of lead investigational therapeutic cancer vaccine, IO102-IO103, in combination with KEYTRUDA® (pembrolizumab), in patients with advanced melanoma; planned interim analysis for overall response rate (ORR) expected in third quarter of 2024 by independent data monitoring committeeProgressed clinical development of IO102-IO103 with first patient dosed in Phase 2 basket trial of IO102-IO103 in combination with pembrolizumab as neoadjuvant and adjuvant treatment of patients with resectable solid tumorsEnded 2023 with cash and cash equivalents of approximately $143.2 million; expected operational runway into the fourth quarter of 2025 NEW YORK, March
Enrollment in the company's Phase 3 pivotal trial (IOB-013/KN-D18) in advanced melanoma accelerated in the second half of 2022; the company expects to enroll 75% of patients by mid-2023 and fully enroll the trial by the end of 2023.The Phase 3 trial protocol calls for an interim analysis of overall response rate one year after 75% of patients have been randomized; this interim analysis could allow for submission of a Biologics License Application for an accelerated approval in the United States.The company continues to enroll patients in its Phase 2 basket study (IOB-022/KN-D38) evaluating IO102-IO103 in combination with pembrolizumab in patients with non-small cell lung cancer, head and nec
Clinical trial site activation, a leading indicator of patient enrollment, has accelerated in the past three months in the company's global Phase 3 combination trial of IO102-IO103 and KEYTRUDA® (pembrolizumab) as first-line treatment in advanced melanoma Oral presentation and two poster presentations at the Society for Immunotherapy of Cancer's (SITC) 37thAnnual Meeting this week will provide an overview of the Phase 1/2 study (MM1636) with IO102-IO103 in combination with nivolumab for metastatic melanoma and discuss preclinical work on the next two candidates in the IO Biotech pipeline, which target the immunosuppressive effects of Arginase 1 (ARG1) and Transforming Growth Factor Beta 1 (
Pivotal Phase 3 trial (IOB-013/KN-D18) evaluating off-the-shelf therapeutic cancer vaccine IO102-IO103 in combination with Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with advanced melanoma on track with primary endpoint of progression free survival (PFS) projected to be reached in first half of 2025Primary endpoint met in Phase 2 basket trial (IOB-022/KN-D38) cohort evaluating IO102-IO103 in combination with pembrolizumab in the first-line treatment of advanced squamous cell carcinoma of the head and neck (SCCHN)Enrollment in Phase 2 basket trial (IOB-032/PN-E40) evaluating IO102-IO103 in combination with pembrolizumab as neoadjuvant and adjuvant treatment of patients wi
NEW YORK, Nov. 11, 2024 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that members of its senior management team will participate in the following upcoming investor conferences: Event: Jefferies London Healthcare ConferenceLocation: LondonOne-on-one meetings: Wednesday, November 20, 2024Participants: Mai-Britt Zocca, PhD, President and CEO and Amy Sullivan, CFO Event: Piper Sandler 36th Annual Healthcare ConferenceLocation: New York, New YorkFireside chat: Tuesday, December 3, 2024 at 11:00 am ETPresenter: Mai-Britt Zocca,
-- Metastatic non-small cell lung cancer (NSCLC) patients treated in the first line setting with IO102-IO103 in combination with Keytruda® demonstrated promising activity with an overall response rate of 55% unconfirmed/48% confirmed, disease control rate of 81%, and approximately 50% of patients without disease progression at 12 months; median duration of response not reached -- -- Safety profile consistent with prior studies with the combination, showing no unexpected toxicities compared to anti-PD1 monotherapy, and low-grade transient injection site reactions as the most common treatment related adverse event -- -- The data from this NSCLC cohort combined with the recent positive squamo
4 - IO Biotech, Inc. (0001865494) (Issuer)
10-Q - IO Biotech, Inc. (0001865494) (Filer)
8-K - IO Biotech, Inc. (0001865494) (Filer)
144 - IO Biotech, Inc. (0001865494) (Subject)
4 - IO Biotech, Inc. (0001865494) (Issuer)
4 - IO Biotech, Inc. (0001865494) (Issuer)
4 - IO Biotech, Inc. (0001865494) (Issuer)
HC Wainwright & Co. analyst Emily Bodnar maintains IO Biotech (NASDAQ:IOBT) with a Buy and raises the price target from $8 to $12.
Gainers SCWorx (NASDAQ:WORX) stock increased by 60.8% to $2.75 during Wednesday's after-market session. The market value of their outstanding shares is at $3.3 million. IO Biotech (NASDAQ:IOBT) stock increased by 11.44% to $1.85. The company's market cap stands at $121.8 million. As per the press release, Q4 earnings came out yesterday. Artelo Biosciences (NASDAQ:ARTL) stock moved upwards by 8.11% to $1.6. The market value of their outstanding shares is at $5.1 million. NextCure (NASDAQ:NXTC) shares increased by 8.01% to $1.82. The market value of their outstanding shares is at $50.7 million. Atara Biotherapeutics (NASDAQ:ATRA) shares moved upwards by 7.47% to $0.75. The market value of
SC 13G/A - IO Biotech, Inc. (0001865494) (Subject)
SC 13D/A - IO Biotech, Inc. (0001865494) (Subject)
SC 13G/A - IO Biotech, Inc. (0001865494) (Subject)
Morgan Stanley initiated coverage of IO Biotech with a rating of Overweight and set a new price target of $21.00
Cowen & Co. initiated coverage of IO Biotech with a rating of Outperform
Jefferies initiated coverage of IO Biotech with a rating of Buy and set a new price target of $20.00